TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33086652

Group type: EXPERIMENTAL
Intervention: Vitamin D levels <30 nmol/L in the first trimester
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Vitamin D levels <20 nmol/L in the first trimester
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Vitamin D levels <30 nmol/L in the third trimester
Number of subjects: 422
Study: 34366293

Group type: EXPERIMENTAL
Intervention: Bhramari pranayama (Bhr. P) for 45 min, thrice a week for six months
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study: 34922436

Group type: EXPERIMENTAL
Intervention: Quarterly fremanezumab
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: Monthly fremanezumab
Number of subjects: 837

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 837
Study: 35669488

Group type: EXPERIMENTAL
Intervention: PAX Good Behaviour Game implementation intervention
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PAX Good Behaviour Game
Number of subjects: 40
Study: 32666123

Group type: EXPERIMENTAL
Intervention: Lusutrombopag 0.75 mg for 6 days (first dose: 1.5 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cyclosporine 400-600 mg
Number of subjects: 31
Study: 35342620

Group type: EXPERIMENTAL
Intervention: Active Remote Ischemic Conditioning (RIC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham Remote Ischemic Conditioning (RIC)
Number of subjects: 16
Study: 32969169

Group type: EXPERIMENTAL
Intervention: Adj‐BFA (Battlefield acupuncture)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Adj‐Sham (sham acupuncture)
Number of subjects: 90

Group type: COMPARATOR
Intervention: SAC (standard analgesia care)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Adj‐BFA, Adj‐Sham, SAC
Number of subjects: 90
Study: 35562030

Group type: EXPERIMENTAL
Intervention: Telemedicine examination (video-guided)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Telemedicine maneuvers examining ROM limitations
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Telemedicine maneuvers identifying apprehension associated with glenohumeral instability
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Telemedicine experience
Number of subjects: 32
Study: 33207285

Group type: EXPERIMENTAL
Intervention: Emotion induction condition (sadness only)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Emotion induction condition (anger only)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Emotion induction condition (sadness and anger)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Rumination induction
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 117
Study: 32497779

Group type: EXPERIMENTAL
Intervention: Synbiotic 2000
Number of subjects: 182
Study: 35086230

Group type: EXPERIMENTAL
Intervention: Surgeon-cut DSAEK
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-cut DSAEK
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-loaded DSAEK
Number of subjects: 0
Study: 34055723

Group type: EXPERIMENTAL
Intervention: Social Norms feedback intervention
Number of subjects: 4463

Group type: COMPARATOR
Intervention: Control group (delayed intervention)
Number of subjects: 4463
Study: 32562877

Group type: EXPERIMENTAL
Intervention: Reslizumab 3.0 mg/kg every 4 weeks for 1 year
Number of subjects: 953

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 953
Study: 36045765

Group type: EXPERIMENTAL
Intervention: Indirect-composite-resin (ICR) crowns
Number of subjects: 20

Group type: COMPARATOR
Intervention: Porcelain-fused-to-metal (PFM) crowns
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overall implant survival
Number of subjects: 20
Study: 33524367

Group type: EXPERIMENTAL
Intervention: Netarsudil 0.02%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 20
Study: 35211980

Group type: EXPERIMENTAL
Intervention: PRBC transfusion volume based on patient's weight (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: PRBC volume calculated using a formula (Group B)
Number of subjects: 60
Study: 35933379

Group type: EXPERIMENTAL
Intervention: Lacrystim® treatment (3 IPL sessions at D0, D15, and D45 with 4 shots per side at a fluence of 8 mJ/cm2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lacrystim® treatment
Number of subjects: 45
Study: 32172362

Group type: EXPERIMENTAL
Intervention: Motivational Physical Activity Intervention (MPAI) for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 616599967

Group type: EXPERIMENTAL
Intervention: JASPER parent‐mediated intervention
Number of subjects: 86

Group type: COMPARATOR
Intervention: Psychoeducational intervention
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Mirrored pacing strategy
Number of subjects: 86
Study: 34705783

Group type: EXPERIMENTAL
Intervention: Three-segment surgically assisted rapid maxillary expansion
Number of subjects: 32

Group type: COMPARATOR
Intervention: Two-segment surgically assisted rapid maxillary expansion
Number of subjects: 32
Study: 32617609

Group type: EXPERIMENTAL
Intervention: Combined ACL and ALL reconstruction (group B)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Isolated ACL reconstruction (ACLR) (group A)
Number of subjects: 107
Study: 35196668

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (chemotherapy and radiation therapy)
Number of subjects: 109

Group type: COMPARATOR
Intervention: No adjuvant therapy
Number of subjects: 109
Study: 33235112

Group type: EXPERIMENTAL
Intervention: Enteral nutrition combined with accelerated rehabilitation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine nutrition (Control)
Number of subjects: 100
Study: 32482570

Group type: EXPERIMENTAL
Intervention: Septoplasty combined with turbinoplasty
Number of subjects: 137

Group type: COMPARATOR
Intervention: Septoplasty alone
Number of subjects: 137
Study: 36064436

Group type: EXPERIMENTAL
Intervention: BEAM app-based program
Number of subjects: 140

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 140
Study: 33250396

Group type: EXPERIMENTAL
Intervention: Therapy program with strengthening (Group 1, n = 38)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Therapy program without strengthening (Group 2, n = 21)
Number of subjects: 94
Study: 33524052

Group type: EXPERIMENTAL
Intervention: Brucella antibodies by IgG ELISA
Number of subjects: 4746

Group type: EXPERIMENTAL
Intervention: Brucella antibodies by IgM ELISA
Number of subjects: 4746

Group type: EXPERIMENTAL
Intervention: Brucella antibodies by RBT
Number of subjects: 4746

Group type: EXPERIMENTAL
Intervention: TaqMan Array Card (TAC) testing
Number of subjects: 4746

Group type: EXPERIMENTAL
Intervention: Confirmed brucellosis cases
Number of subjects: 4746
Study: 33208303

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) treatment
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (no HFNC)
Number of subjects: 74
Study: 35999942

Group type: EXPERIMENTAL
Intervention: Repeat pulmonary rehabilitation program
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Repeat pulmonary rehabilitation program (twice in 12 months)
Number of subjects: 907
Study: 34654584

Group type: EXPERIMENTAL
Intervention: High VRSA dosage (H-VRSA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low VRSA dosage (L-VRSA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Services as Usual (SAU)
Number of subjects: 0
Study: 34705756

Group type: COMPARATOR
Intervention: IV TXA alone (group IV, n = 48)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: IV TXA followed by oral TXA for 2 days (group 2D, n = 46)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: IV TXA followed by oral TXA for 5 days (group 5D, n = 47)
Number of subjects: 141
Study: 32331034

Group type: EXPERIMENTAL
Intervention: Pimavanserin (PIM) 34 mg/day
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 203
Study: 35364638

Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS (LF-rTMS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS (HF-rTMS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 60
Study: 32910030

Group type: EXPERIMENTAL
Intervention: Fractional picosecond 1064-nm laser (FxPico)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Fractional carbon dioxide laser (FxCO2)
Number of subjects: 25
Study: 36418455

Group type: EXPERIMENTAL
Intervention: Nordic walking with integrated resistance shock absorber (RSA)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nordic walking with classic poles (NW)
Number of subjects: 25
Study: 32386721

Group type: EXPERIMENTAL
Intervention: Dolutegravir
Number of subjects: 268

Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 268

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 268
Study: 33109476

Group type: EXPERIMENTAL
Intervention: Magic Touch sirolimus coated-balloon (SCB)
Number of subjects: 114

Group type: COMPARATOR
Intervention: SeQuent Please Neo paclitaxel coated balloon (PCB)
Number of subjects: 114
Study: 36114080

Group type: EXPERIMENTAL
Intervention: Simulation-based Training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 33122892

Group type: EXPERIMENTAL
Intervention: Evogliptin 5 mg once daily for 7 days (EVO)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Co-administration of evogliptin 5 mg and pioglitazone 30 mg once daily for 7 days (EVO+PIO)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Pioglitazone 30 mg once daily for 7 days (PIO)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: EVO+PIO
Number of subjects: 34
Study: 34229571

Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Random
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Effort
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: NO
Number of subjects: 4
Study: 34516312

Group type: EXPERIMENTAL
Intervention: 20 mg of intravenous Solumedrol every 8 hours for 7 days
Number of subjects: 43

Group type: COMPARATOR
Intervention: Matching placebo every 8 hours for 7 days
Number of subjects: 43
Study: 33932648

Group type: EXPERIMENTAL
Intervention: Concealing the hydration fluid bottle during hydration
Number of subjects: 62

Group type: COMPARATOR
Intervention: Routine procedure (No concealment intervention) during hydration
Number of subjects: 62
Study: 35657079

Group type: EXPERIMENTAL
Intervention: Ibrutinib (560 mg, orally once daily) plus bendamustine (90 mg/m²) and rituximab (375 mg/m²)
Number of subjects: 523

Group type: COMPARATOR
Intervention: Placebo plus bendamustine (90 mg/m²) and rituximab (375 mg/m²)
Number of subjects: 523
Study: 34023288

Group type: EXPERIMENTAL
Intervention: Laser therapy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Routine postoperative intervention
Number of subjects: 82
Study: 32023423

Group type: EXPERIMENTAL
Intervention: MPR technique
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: SCS technique
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: INIT technique
Number of subjects: 48
Study: 32456475

Group type: EXPERIMENTAL
Intervention: coached feigning of ADHD
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: coached feigning of depression and anxiety (DA)
Number of subjects: 75

Group type: COMPARATOR
Intervention: honest responding (HR)
Number of subjects: 75
Study: 33839205

Group type: EXPERIMENTAL
Intervention: Radical radiotherapy
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: NTCP model for predicting ANCSA
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Calibration test for NTCP model
Number of subjects: 548
Study: 35675356

Group type: EXPERIMENTAL
Intervention: Cochlear implants with additional visual cues
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cochlear implants alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hearing aids in the contralateral ear
Number of subjects: 16

Group type: COMPARATOR
Intervention: Audio-only condition
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Audio-visual condition
Number of subjects: 16
Study: 34265407

Group type: EXPERIMENTAL
Intervention: Nifurtimox 30 mg tablet formulations (slow, medium, fast dissolution)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nifurtimox 30 mg with high-fat/high-calorie meal
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nifurtimox 30 mg with low-fat meal
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nifurtimox 30 mg with dairy-based meal
Number of subjects: 60
Study: 34852767

Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride (1.5 mg/kg induction and 2 mg/kg/h maintenance)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 40
Study: 34971713

Group type: EXPERIMENTAL
Intervention: Enhanced Cognitive protocol
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control protocol
Number of subjects: 200
Study: 33971764

Group type: EXPERIMENTAL
Intervention: 8-session psychoeducational program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 60
Study: 33032643

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) boost of 18 Gy in 3 fractions
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) boost of 21 Gy in 3 fractions
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Combination of ADT, WPRT, and SBRT boosts
Number of subjects: 26
Study: 36163947

Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Number of subjects: 34

Group type: COMPARATOR
Intervention: Ravulizumab
Number of subjects: 34

Group type: COMPARATOR
Intervention: Eculizumab
Number of subjects: 34
Study: 34039435

Group type: EXPERIMENTAL
Intervention: Sunflower seed oil (SSO)
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Aquaphor®
Number of subjects: 497

Group type: COMPARATOR
Intervention: Control (neither SSO nor Aquaphor)
Number of subjects: 497
Study: 35776146

Group type: EXPERIMENTAL
Intervention: Whole-tumor ADC measurements
Number of subjects: 170

Group type: COMPARATOR
Intervention: Single-slice ADC measurements
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Clinical-radiological model
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Radiomics model
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Combined model
Number of subjects: 170
Study: 34298438

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (30 mg oral)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 33055122

Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (RIC) once daily for 30 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (RIC) twice daily for 30 days
Number of subjects: 24
Study: 33651731

Group type: EXPERIMENTAL
Intervention: Strength training program with random recovery times between sets (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 20
Study: 33539761

Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring (DVR)
Number of subjects: 941
Study: 32011721

Group type: EXPERIMENTAL
Intervention: Text2Connect intervention (series of text messages)
Number of subjects: 3719

Group type: EXPERIMENTAL
Intervention: Text2Connect intervention (response efficacy messages used)
Number of subjects: 3719

Group type: EXPERIMENTAL
Intervention: Text2Connect intervention (message framing)
Number of subjects: 3719

Group type: EXPERIMENTAL
Intervention: Text2Connect intervention (overall acceptance)
Number of subjects: 3719

Group type: EXPERIMENTAL
Intervention: Text2Connect intervention (response rate)
Number of subjects: 3719

Group type: EXPERIMENTAL
Intervention: Text2Connect intervention (self-efficacy messaging)
Number of subjects: 3719
Study: 35073301

Group type: EXPERIMENTAL
Intervention: Multisensory stimulation training
Number of subjects: 80

Group type: COMPARATOR
Intervention: Audiovisual training
Number of subjects: 80
Study: 33730454

Group type: EXPERIMENTAL
Intervention: VRC01 low-dose group (10 mg/kg)
Number of subjects: 4623

Group type: EXPERIMENTAL
Intervention: VRC01 high-dose group (30 mg/kg)
Number of subjects: 4623

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 4623

Group type: EXPERIMENTAL
Intervention: Pooled VRC01 groups
Number of subjects: 4623

Group type: EXPERIMENTAL
Intervention: VRC01 recipients
Number of subjects: 4623

Group type: COMPARATOR
Intervention: Placebo recipients
Number of subjects: 4623
Study: 616874768

Group type: EXPERIMENTAL
Intervention: Female within the healthy weight range
Number of subjects: 201

Group type: COMPARATOR
Intervention: Female with obesity
Number of subjects: 201
Study: 35112416

Group type: EXPERIMENTAL
Intervention: First wave of COVID-19
Number of subjects: 42253
Study: 34043029

Group type: EXPERIMENTAL
Intervention: Minimally invasive transpiriformis approach
Number of subjects: 106

Group type: COMPARATOR
Intervention: Posterolateral approach
Number of subjects: 106
Study: 32628117

Group type: EXPERIMENTAL
Intervention: CaringGuidance (unguided web-based psychoeducational distress self-management program)
Number of subjects: 54
Study: 35775042

Group type: EXPERIMENTAL
Intervention: Dual-target group (SASD bursa and LHBT sheath corticosteroid injection)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Single-target group (SASD bursa corticosteroid injection alone)
Number of subjects: 60
Study: 33184084

Group type: EXPERIMENTAL
Intervention: Intranasal 1.4 mg naloxone
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intramuscular 0.8 mg naloxone
Number of subjects: 200
Study: 33357171

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention aimed at preventing aggression in PWD
Number of subjects: 228

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 228
Study: 33211124

Group type: EXPERIMENTAL
Intervention: Routine interventional strategy in addition to optimal medical therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CTA) as a diagnostic tool
Number of subjects: 0
Study: 35412416

Group type: EXPERIMENTAL
Intervention: Home quarantine
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (people seeking laboratory testing for suspected Sars-CoV-2 infection)
Number of subjects: 57
Study: 35262901

Group type: EXPERIMENTAL
Intervention: MSB11022 via Autoinjector (AI)
Number of subjects: 216

Group type: COMPARATOR
Intervention: MSB11022 via Pre-filled Syringe (PFS)
Number of subjects: 216
Study: 33313734

Group type: EXPERIMENTAL
Intervention: Whole Health Team (WHT)
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Primary Care Group Education (PC-GE)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Usual VA Primary Care (UPC)
Number of subjects: 750
Study: 35544130

Group type: EXPERIMENTAL
Intervention: Pegulicianine fluorescence-guided system (pFGS)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Standard pathology assessment
Number of subjects: 234
Study: 32900583

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (100 billion cfu/day of Lactococcus lactis subsp. Lactis LL358, Lactobaccillus salivarius LS159, Lactobaccillus pentosus LPE588) for 6 months
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 56
Study: 33645398

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Non-synchronized Nasal Intermittent Positive Pressure Ventilation (nsNIPPV)
Number of subjects: 11
Study: 32444296

Group type: EXPERIMENTAL
Intervention: Intracutaneous sterile water injection (ISWI)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (75 mg intramuscular injection)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (0.5 cm3 isotonic saline injection)
Number of subjects: 150
Study: 32668410

Group type: EXPERIMENTAL
Intervention: Continuous Training Group (CTG)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Interval Training Group (ITG)
Number of subjects: 41
Study: 36342854

Group type: EXPERIMENTAL
Intervention: Direct instruction
Number of subjects: 81

Group type: COMPARATOR
Intervention: Indirect exposure
Number of subjects: 81
Study: 34130783

Group type: EXPERIMENTAL
Intervention: Rehabilitation treatment based on ICF-CY Core Sets
Number of subjects: 122

Group type: COMPARATOR
Intervention: Traditional rehabilitation mode (Control)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Environmental factors intervention in observation group
Number of subjects: 122
Study: 33361100

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (500 mg, three times daily for 5 days)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Number of subjects: 392

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study: 32979076

Group type: EXPERIMENTAL
Intervention: Walnut supplementation (15% of total energy, ≈30–60 g/day)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control (abstaining from walnuts)
Number of subjects: 211
Study: 35055603

Group type: EXPERIMENTAL
Intervention: Informative video intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Verbal standard information (Control)
Number of subjects: 120
Study: 32975164

Group type: EXPERIMENTAL
Intervention: MFS features (graph, expected change trajectory line, alert, treatment suggestions)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Graphs
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: All MFS features
Number of subjects: 299
Study: 32556354

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injection (Group 1)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy (Group 2)
Number of subjects: 68
Study: 35656988

Group type: EXPERIMENTAL
Intervention: WATCH-DM score
Number of subjects: 12028

Group type: EXPERIMENTAL
Intervention: TRS-HFDM score
Number of subjects: 12028
Study: 34351376

Group type: EXPERIMENTAL
Intervention: Oxycodone rescue (oxycodone, 5 mg as second-line therapy)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Ibuprofen rescue (ibuprofen, 600 mg as second-line therapy)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Oxycodone rescue
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Ibuprofen rescue
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 118

Group type: COMPARATOR
Intervention: Nonopioid users (acetaminophen only or acetaminophen and ibuprofen)
Number of subjects: 118
Study: 33180513

Group type: EXPERIMENTAL
Intervention: Short-term dynamic psychotherapy
Number of subjects: 65